Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of non-genotype 1 hepatitis C virus patients.

Current gastroenterology reports - 1 Feb 2012

Mangia Alessandra, Mottola Leonardo

Abstract excerpt

The HCV genotype will remain an important, independent pre-treatment predictor of virological response. While direct acting antivirals (DAA) will improve in the coming months the rates of virological response in patients with HCV-1, the development of DAAs effective against other HCV genotypes is at an earlier stage. Therefore, Peg-Interferon and Ribavirin will continue to be used in the near future as standard...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Genotype
Share to Hepacivirus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C

Share to Interferons

Share to Interleukins

Share to Polymorphism, Single Nucleotide

Share to RNA, Viral

Source

Identifiers

PMID: 22113745
DOI: 10.1007/s11894-011-0235-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of non-genotype 1 hepatitis C virus patients.PMID 22113745Read ↗

[Treatment of non-1 genotype chronic hepatitis C patients].Semantic proximity Read ↗

What's new in HCV genotype 2 treatment.Semantic proximity Read ↗

IL28B polymorphism -- predictive factor of HCV infected genotype 1 individuals to treatment response and management of therapy.Semantic proximity Read ↗

Hepatitis C Virus: Current and Evolving Treatments for Genotypes 2 and 3.Semantic proximity Read ↗

Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.Semantic proximity Read ↗

Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study.Semantic proximity Read ↗

Role of viral and host factors in interferon based therapy of hepatitis C virus infection.Semantic proximity Read ↗

IFN-λ gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitors.Semantic proximity Read ↗

Interleukin-28b CC genotype predicts early treatment response and CT/TT genotypes predicts non-response in patients infected with HCV genotype 3.Semantic proximity Read ↗

The role of pharmacogenetics in the treatment of chronic hepatitis C infection.Semantic proximity Read ↗

Hepatitis C virus infection: Are there still specific problems with genotype 3?Semantic proximity Read ↗

Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.